GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Covidien PLC (FRA:6COP) » Definitions » Operating Margin %

Covidien (FRA:6COP) Operating Margin % : 24.13% (As of Dec. 2014)


View and export this data going back to . Start your Free Trial

What is Covidien Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Covidien's Operating Income for the three months ended in Dec. 2014 was €526 Mil. Covidien's Revenue for the three months ended in Dec. 2014 was €2,178 Mil. Therefore, Covidien's Operating Margin % for the quarter that ended in Dec. 2014 was 24.13%.

Good Sign:

Covidien PLC operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Covidien's Operating Margin % or its related term are showing as below:

FRA:6COP' s Operating Margin % Range Over the Past 10 Years
Min: 4.31   Med: 20.83   Max: 26.05
Current: 19.7


FRA:6COP's Operating Margin % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.27 vs FRA:6COP: 19.70

Covidien's 5-Year Average Operating Margin % Growth Rate was 1.30% per year.

Covidien's Operating Income for the three months ended in Dec. 2014 was €526 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2014 was €1,614 Mil.


Covidien Operating Margin % Historical Data

The historical data trend for Covidien's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Covidien Operating Margin % Chart

Covidien Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.78 20.52 21.17 20.83 18.69

Covidien Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.12 22.40 13.62 18.76 24.13

Competitive Comparison of Covidien's Operating Margin %

For the Medical Instruments & Supplies subindustry, Covidien's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Covidien's Operating Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Covidien's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Covidien's Operating Margin % falls into.



Covidien Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Covidien's Operating Margin % for the fiscal year that ended in Sep. 2014 is calculated as

Operating Margin %=Operating Income (A: Sep. 2014 ) / Revenue (A: Sep. 2014 )
=1545.792 / 8271.384
=18.69 %

Covidien's Operating Margin % for the quarter that ended in Dec. 2014 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2014 ) / Revenue (Q: Dec. 2014 )
=525.528 / 2178.346
=24.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Covidien  (FRA:6COP) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Covidien Operating Margin % Related Terms

Thank you for viewing the detailed overview of Covidien's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Covidien (FRA:6COP) Business Description

Traded in Other Exchanges
N/A
Address
Covidien PLC formerly known as Covidien Ltd. was incorporated in Bermuda in 2000 as a wholly-owned subsidiary of Tyco International Ltd. In June 2009, Covidien plc announced that one of its subsidiaries has completed the acquisition of VNUS Medical Technologies, Inc. In September 2009, the Company completed the acquisition of Power Medical Interventions Inc. In November 2009, the Company completed the acquisition of Aspect Medical Systems Inc. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Its products are found in almost every hospital in the United States. Its mission is to create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals. It operates through two segments: Medical Devices and Medical Supplies. The Medical Devices segment includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products, and other medical products. The Medical Supplies segment includes the development, manufacture and sale of nursing care products, medical surgical products, SharpSafety products and original equipment manufacturer products. Competitors of Medical Devices segment include diversified healthcare companies, such as Johnson & Johnson, Boston Scientific, Baxter and C.R. Bard. Its Nursing Care products include: Curity and Kerlix and Medical Surgical products include: Medi-Trace. The Company holds more than 13,000 patents and have over 10,500 patent applications pending in the United States and in certain other countries that relate to aspects of the technology used in many of its products. The Company is subject to numerous federal, state and local environmental protection and health and safety laws and regulations both within and outside the United States.

Covidien (FRA:6COP) Headlines

No Headlines